Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | EIF4E | P06730 | 2/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.42 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.42 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2056678 | 0.82 | ALDH1A1 (0.46) | ALDH1A1HPGDEIF4EIRAK4CYP19A1 | |
| SCHEMBL5342437 | 0.82 | ALDH1A1 (0.65) | ALDH1A1HPGDEIF4EIRAK4CYP19A1 | |
| SCHEMBL26319825 | 0.75 | ALDH1A1 (0.54) | ALDH1A1EIF4EACHEPTGER1MEN1 | |
| SCHEMBL9823724 | 0.71 | ALDH1A1 (0.63) | ALDH1A1HPGDACHE | |
| SCHEMBL4775930 | 0.71 | ALDH1A1 (0.57) | ALDH1A1HPGDPIN1DHODH | |
| SCHEMBL5342686 | 0.70 | SMN1; SMN2 (0.60) | ALDH1A1HPGDIRAK4MEN1KMT2A | |
| SCHEMBL9823776 | 0.70 | CYP19A1 (0.56) | ALDH1A1EIF4ECYP19A1ACHEPTGER1 | |
| SCHEMBL9823342 | 0.70 | CYP1A1 (0.63) | ALDH1A1HPGDIRAK4ACHECSNK2A1 | |
| SCHEMBL4601727 | 0.69 | DHODH (0.59) | ALDH1A1HPGDPIN1DHODH | |
| SCHEMBL3957201 | 0.69 | ALDH1A1 (0.69) | ALDH1A1HPGDCYP19A1PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105491-A1 | THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-05-05 | — | — | US | disclosed |
| WO-2010004507-A1 | THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105491-A1 | THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | ALDH1A1 690/4885HPGD 2597/4885EIF4E 2373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.